Click for best price
NonInsulin Therapies for Diabetes Market Size, Share 2022
This report contains market size and forecasts of Non-Insulin Therapies for Diabetes in Global, including the following market information:
Global Non-Insulin Therapies for Diabetes Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-Insulin Therapies for Diabetes market was valued at 32870 million in 2021 and is projected to reach US$ 58240 million by 2028, at a CAGR of 8.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Alpha-glucosidase Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-Insulin Therapies for Diabetes include GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Pfizer, Merck, Dong-A Pharmaceutical and Luye Pharma Group, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Insulin Therapies for Diabetes companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Insulin Therapies for Diabetes Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, by Type, 2021 (%)
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
Global Non-Insulin Therapies for Diabetes Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, by Application, 2021 (%)
Monitoring
Diagnosis
Treatment
Others
Global Non-Insulin Therapies for Diabetes Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Non-Insulin Therapies for Diabetes Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Insulin Therapies for Diabetes revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-Insulin Therapies for Diabetes revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
| Report Attributes |
Report Details |
| Report Title |
Non-Insulin Therapies for Diabetes Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
116 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Insulin Therapies for Diabetes Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Insulin Therapies for Diabetes Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Insulin Therapies for Diabetes Overall Market Size
2.1 Global Non-Insulin Therapies for Diabetes Market Size: 2021 VS 2028
2.2 Global Non-Insulin Therapies for Diabetes Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Insulin Therapies for Diabetes Players in Global Market
3.2 Top Global Non-Insulin Therapies for Diabetes Companies Ranked by Revenue
3.3 Global Non-Insulin Therapies for Diabetes Revenue by Companies
3.4 Top 3 and Top 5 Non-Insulin Therapies for Diabetes Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-Insulin Therapies for Diabetes Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Insulin Therapies for Diabetes Players in Global Market
3.6.1 List of Global Tier 1 Non-Insulin Therapies for Diabetes Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Insulin Therapies for Diabetes Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Non-Insulin Therapies for Diabetes Market Size Markets, 2021 & 2028
4.1.2 Alpha-glucosidase Inhibitors
4.1.3 Amylin Agonists
4.1.4 Biguanides
4.1.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
4.1.6 Glinides / Meglitinides
4.1.7 GLP-1 Analogs / GLP-1 Agonists
4.1.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
4.1.9 Sulfonylureas
4.1.10 Thiazolidinediones
4.1.11 Others
4.2 By Type - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
4.2.1 By Type - Global Non-Insulin Therapies for Diabetes Revenue, 2017-2022
4.2.2 By Type - Global Non-Insulin Therapies for Diabetes Revenue, 2023-2028
4.2.3 By Type - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Insulin Therapies for Diabetes Market Size, 2021 & 2028
5.1.2 Monitoring
5.1.3 Diagnosis
5.1.4 Treatment
5.1.5 Others
5.2 By Application - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
5.2.1 By Application - Global Non-Insulin Therapies for Diabetes Revenue, 2017-2022
5.2.2 By Application - Global Non-Insulin Therapies for Diabetes Revenue, 2023-2028
5.2.3 By Application - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Non-Insulin Therapies for Diabetes Market Size, 2021 & 2028
6.2 By Region - Global Non-Insulin Therapies for Diabetes Revenue & Forecasts
6.2.1 By Region - Global Non-Insulin Therapies for Diabetes Revenue, 2017-2022
6.2.2 By Region - Global Non-Insulin Therapies for Diabetes Revenue, 2023-2028
6.2.3 By Region - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.3.2 US Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.3.3 Canada Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.3.4 Mexico Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.4.2 Germany Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.3 France Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.4 U.K. Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.5 Italy Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.6 Russia Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.7 Nordic Countries Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.4.8 Benelux Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.5.2 China Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5.3 Japan Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5.4 South Korea Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5.5 Southeast Asia Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.5.6 India Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.6.2 Brazil Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.6.3 Argentina Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue, 2017-2028
6.7.2 Turkey Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.7.3 Israel Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.7.4 Saudi Arabia Non-Insulin Therapies for Diabetes Market Size, 2017-2028
6.7.5 UAE Non-Insulin Therapies for Diabetes Market Size, 2017-2028
7 Players Profiles
7.1 GSK
7.1.1 GSK Corporate Summary
7.1.2 GSK Business Overview
7.1.3 GSK Non-Insulin Therapies for Diabetes Major Product Offerings
7.1.4 GSK Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.1.5 GSK Key News
7.2 Eli Lilly
7.2.1 Eli Lilly Corporate Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Major Product Offerings
7.2.4 Eli Lilly Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.2.5 Eli Lilly Key News
7.3 Sumitomo Dainippon Pharma
7.3.1 Sumitomo Dainippon Pharma Corporate Summary
7.3.2 Sumitomo Dainippon Pharma Business Overview
7.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Major Product Offerings
7.3.4 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.3.5 Sumitomo Dainippon Pharma Key News
7.4 Intarcia Therapeutics
7.4.1 Intarcia Therapeutics Corporate Summary
7.4.2 Intarcia Therapeutics Business Overview
7.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Major Product Offerings
7.4.4 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.4.5 Intarcia Therapeutics Key News
7.5 Servier
7.5.1 Servier Corporate Summary
7.5.2 Servier Business Overview
7.5.3 Servier Non-Insulin Therapies for Diabetes Major Product Offerings
7.5.4 Servier Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.5.5 Servier Key News
7.6 Pfizer
7.6.1 Pfizer Corporate Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Non-Insulin Therapies for Diabetes Major Product Offerings
7.6.4 Pfizer Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.6.5 Pfizer Key News
7.7 Merck
7.7.1 Merck Corporate Summary
7.7.2 Merck Business Overview
7.7.3 Merck Non-Insulin Therapies for Diabetes Major Product Offerings
7.7.4 Merck Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.7.5 Merck Key News
7.8 Dong-A Pharmaceutical
7.8.1 Dong-A Pharmaceutical Corporate Summary
7.8.2 Dong-A Pharmaceutical Business Overview
7.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Major Product Offerings
7.8.4 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.8.5 Dong-A Pharmaceutical Key News
7.9 Luye Pharma Group
7.9.1 Luye Pharma Group Corporate Summary
7.9.2 Luye Pharma Group Business Overview
7.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Major Product Offerings
7.9.4 Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.9.5 Luye Pharma Group Key News
7.10 Eurofarma
7.10.1 Eurofarma Corporate Summary
7.10.2 Eurofarma Business Overview
7.10.3 Eurofarma Non-Insulin Therapies for Diabetes Major Product Offerings
7.10.4 Eurofarma Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.10.5 Eurofarma Key News
7.11 Geropharm
7.11.1 Geropharm Corporate Summary
7.11.2 Geropharm Business Overview
7.11.3 Geropharm Non-Insulin Therapies for Diabetes Major Product Offerings
7.11.4 Geropharm Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.11.5 Geropharm Key News
7.12 Alkem Labs
7.12.1 Alkem Labs Corporate Summary
7.12.2 Alkem Labs Business Overview
7.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Major Product Offerings
7.12.4 Alkem Labs Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.12.5 Alkem Labs Key News
7.13 SatRx
7.13.1 SatRx Corporate Summary
7.13.2 SatRx Business Overview
7.13.3 SatRx Non-Insulin Therapies for Diabetes Major Product Offerings
7.13.4 SatRx Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.13.5 SatRx Key News
7.14 Jiangsu Hansoh Pharmaceutical
7.14.1 Jiangsu Hansoh Pharmaceutical Corporate Summary
7.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
7.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Major Product Offerings
7.14.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.14.5 Jiangsu Hansoh Pharmaceutical Key News
7.15 Novo Nordisk
7.15.1 Novo Nordisk Corporate Summary
7.15.2 Novo Nordisk Business Overview
7.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Major Product Offerings
7.15.4 Novo Nordisk Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.15.5 Novo Nordisk Key News
7.16 Emisphere
7.16.1 Emisphere Corporate Summary
7.16.2 Emisphere Business Overview
7.16.3 Emisphere Non-Insulin Therapies for Diabetes Major Product Offerings
7.16.4 Emisphere Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.16.5 Emisphere Key News
7.17 Uni-Bio Science Group
7.17.1 Uni-Bio Science Group Corporate Summary
7.17.2 Uni-Bio Science Group Business Overview
7.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Major Product Offerings
7.17.4 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.17.5 Uni-Bio Science Group Key News
7.18 Takeda
7.18.1 Takeda Corporate Summary
7.18.2 Takeda Business Overview
7.18.3 Takeda Non-Insulin Therapies for Diabetes Major Product Offerings
7.18.4 Takeda Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.18.5 Takeda Key News
7.19 3SBio
7.19.1 3SBio Corporate Summary
7.19.2 3SBio Business Overview
7.19.3 3SBio Non-Insulin Therapies for Diabetes Major Product Offerings
7.19.4 3SBio Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.19.5 3SBio Key News
7.20 Jiangsu Hengrui Medicine
7.20.1 Jiangsu Hengrui Medicine Corporate Summary
7.20.2 Jiangsu Hengrui Medicine Business Overview
7.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Major Product Offerings
7.20.4 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue in Global Market (2017-2022)
7.20.5 Jiangsu Hengrui Medicine Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Insulin Therapies for Diabetes Market Opportunities & Trends in Global Market
Table 2. Non-Insulin Therapies for Diabetes Market Drivers in Global Market
Table 3. Non-Insulin Therapies for Diabetes Market Restraints in Global Market
Table 4. Key Players of Non-Insulin Therapies for Diabetes in Global Market
Table 5. Top Non-Insulin Therapies for Diabetes Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-Insulin Therapies for Diabetes Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-Insulin Therapies for Diabetes Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-Insulin Therapies for Diabetes Product Type
Table 9. List of Global Tier 1 Non-Insulin Therapies for Diabetes Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Insulin Therapies for Diabetes Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-Insulin Therapies for Diabetes Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-Insulin Therapies for Diabetes Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-Insulin Therapies for Diabetes Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-Insulin Therapies for Diabetes Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-Insulin Therapies for Diabetes Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-Insulin Therapies for Diabetes Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2023-2028
Table 30. GSK Corporate Summary
Table 31. GSK Non-Insulin Therapies for Diabetes Product Offerings
Table 32. GSK Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 33. Eli Lilly Corporate Summary
Table 34. Eli Lilly Non-Insulin Therapies for Diabetes Product Offerings
Table 35. Eli Lilly Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 36. Sumitomo Dainippon Pharma Corporate Summary
Table 37. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Offerings
Table 38. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 39. Intarcia Therapeutics Corporate Summary
Table 40. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Offerings
Table 41. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 42. Servier Corporate Summary
Table 43. Servier Non-Insulin Therapies for Diabetes Product Offerings
Table 44. Servier Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 45. Pfizer Corporate Summary
Table 46. Pfizer Non-Insulin Therapies for Diabetes Product Offerings
Table 47. Pfizer Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 48. Merck Corporate Summary
Table 49. Merck Non-Insulin Therapies for Diabetes Product Offerings
Table 50. Merck Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 51. Dong-A Pharmaceutical Corporate Summary
Table 52. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Offerings
Table 53. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 54. Luye Pharma Group Corporate Summary
Table 55. Luye Pharma Group Non-Insulin Therapies for Diabetes Product Offerings
Table 56. Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 57. Eurofarma Corporate Summary
Table 58. Eurofarma Non-Insulin Therapies for Diabetes Product Offerings
Table 59. Eurofarma Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 60. Geropharm Corporate Summary
Table 61. Geropharm Non-Insulin Therapies for Diabetes Product Offerings
Table 62. Geropharm Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 63. Alkem Labs Corporate Summary
Table 64. Alkem Labs Non-Insulin Therapies for Diabetes Product Offerings
Table 65. Alkem Labs Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 66. SatRx Corporate Summary
Table 67. SatRx Non-Insulin Therapies for Diabetes Product Offerings
Table 68. SatRx Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 69. Jiangsu Hansoh Pharmaceutical Corporate Summary
Table 70. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Offerings
Table 71. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 72. Novo Nordisk Corporate Summary
Table 73. Novo Nordisk Non-Insulin Therapies for Diabetes Product Offerings
Table 74. Novo Nordisk Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 75. Emisphere Corporate Summary
Table 76. Emisphere Non-Insulin Therapies for Diabetes Product Offerings
Table 77. Emisphere Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 78. Uni-Bio Science Group Corporate Summary
Table 79. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Offerings
Table 80. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 81. Takeda Corporate Summary
Table 82. Takeda Non-Insulin Therapies for Diabetes Product Offerings
Table 83. Takeda Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 84. 3SBio Corporate Summary
Table 85. 3SBio Non-Insulin Therapies for Diabetes Product Offerings
Table 86. 3SBio Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
Table 87. Jiangsu Hengrui Medicine Corporate Summary
Table 88. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Offerings
Table 89. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Non-Insulin Therapies for Diabetes Segment by Type in 2021
Figure 2. Non-Insulin Therapies for Diabetes Segment by Application in 2021
Figure 3. Global Non-Insulin Therapies for Diabetes Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-Insulin Therapies for Diabetes Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-Insulin Therapies for Diabetes Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2021
Figure 8. By Type - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
Figure 12. US Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
Figure 16. Germany Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
Figure 24. China Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
Figure 30. Brazil Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-Insulin Therapies for Diabetes Revenue Market Share, 2017-2028
Figure 33. Turkey Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-Insulin Therapies for Diabetes Revenue, (US$, Mn), 2017-2028
Figure 37. GSK Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Eli Lilly Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Servier Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Pfizer Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Merck Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Luye Pharma Group Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eurofarma Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Geropharm Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Alkem Labs Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. SatRx Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Novo Nordisk Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Emisphere Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Takeda Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. 3SBio Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
